{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:53:33Z","timestamp":1781636013278,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The combination of systemic immune checkpoint inhibitors with standard of care intravesical Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) has shown potential in enhancing BCG therapeutic effects. However, challenges such as disease recurrence, progression, and immune-related toxicities remain a significant hurdle. Furthermore, the mechanism of action of BCG involves broad, non-specific immune activation. While this recruits bystander CD8\n                      <jats:sup>+<\/jats:sup>\n                      and NK cells, it also triggers the undesired expansion of Tregs, which may ultimately hamper therapeutic efficacy. We aimed to explore the feasibility of a targeted approach designed to overcome intravesical tumor resistance and selectively enhance the expansion and effector functions of CD8\n                      <jats:sup>+<\/jats:sup>\n                      TILs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We tested intravesical administration of BCG with murinized PD1-IL2v, a fusion protein that simultaneously targets PD-1 and IL-2R\u03b2\u03b3 in cis on the same cell, in a preclinical mouse model of NMIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both BCG monotherapy and co-treatment with a murinized PD1-IL2v improved animal survival. Notably, the intravesical combination of BCG and murinized PD1-IL2v significantly increased the number of CD8\n                      <jats:sup>+<\/jats:sup>\n                      TILs with polyfunctional cytotoxic effector phenotype and avoided Treg expansion in contrast to BCG monotherapy. In addition, in patient-derived tumors, we observed a higher frequency of CD8\u207a TILs (18%) compared to Tregs (5%), with 60% of the CD8\n                      <jats:sup>+<\/jats:sup>\n                      TILs expressing PD-1 on their surface, representing a potential target for PD1-IL2v, alias eciskafusp alfa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The intravesical combination of BCG with murinized PD1-IL2v selectively increases the number of cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      TILs, but not Tregs, and improves the survival of the mice in the preclinical model of bladder cancer model. These findings support the rationale for exploring the clinical use of eciskafusp alfa for intravesical administration in high-risk NMIBC patients. The combination of BCG and eciskafusp alfa could be deployable as a second line of treatment for NMIBC patients unresponsive to BCG.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03667-w","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:45:24Z","timestamp":1770788724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD1-IL2v expands and induces effector CD8+ TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model"],"prefix":"10.1186","volume":"45","author":[{"given":"Irene","family":"Locatelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lorenzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Venegoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Coste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithin","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Maria","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Manchala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Hosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Umana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Codarri","family":"Deak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-9158","authenticated-orcid":false,"given":"Massimo","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"3667_CR1","unstructured":"https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer\/chapter\/disease-management. 2025."},{"issue":"4","key":"3667_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1177\/107327480200900403","volume":"9","author":"R Carrion","year":"2002","unstructured":"Carrion R, Seigne J. Surgical management of bladder carcinoma. Cancer Control: J Moffitt Cancer Cent. 2002;9(4):284\u201392.","journal-title":"Cancer Control: J Moffitt Cancer Cent"},{"issue":"11","key":"3667_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","volume":"32","author":"C Yeung","year":"2014","unstructured":"Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. PharmacoEconomics. 2014;32(11):1093\u2013104.","journal-title":"PharmacoEconomics"},{"issue":"7","key":"3667_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3667_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, et al. Phase 2 trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive bladder cancer: SWOG S1605. Eur Urol. 2023;84(6):536\u201344.","journal-title":"Eur Urol"},{"key":"3667_CR6","doi-asserted-by":"crossref","first-page":"S1701","DOI":"10.1016\/S0302-2838(24)01302-2","volume":"85","author":"MP Hern\u00e1ndez-Arroyo \u2219","year":"2024","unstructured":"Hern\u00e1ndez-Arroyo \u2219 MP, Mart\u00edn-Torres \u2219 P. \u00c1lvarez-Rodr\u00edguez \u2219 C. Su\u00e1rez \u2219 L. Morales \u2219 S. Ponce \u2219 A. Rodr\u00edguez-Antol\u00edn \u2219 D. Castellano FG-RGDVMDJPVMGCG-CMR-IM. First results of the phase Ib-II bladdergate clinical trial: intravenous atezolizumab\u2009+\u2009intravesical Bacillus Calmette-Gu\u00e9rin (BCG) upfront combination in BCG-na\u00efve high risk non-muscle invasive bladder cancer patients. Eur Urol. 2024;85:S1701.","journal-title":"Eur Urol"},{"key":"3667_CR7","doi-asserted-by":"crossref","unstructured":"Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025;31(8):2806 .","DOI":"10.1038\/s41591-025-03738-z"},{"key":"3667_CR8","doi-asserted-by":"crossref","unstructured":"Inman BA, Hahn NM, Stratton K, Kopp R, Sankin A, Skinner E et al. A phase 1b\/2 study of Atezolizumab with or without Bacille Calmette-Guerin in patients with High-risk Non-muscle-invasive bladder cancer. Eur Urol Oncol. 2023;6(3):313.","DOI":"10.1016\/j.euo.2023.01.013"},{"key":"3667_CR9","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04387461"},{"key":"3667_CR10","doi-asserted-by":"crossref","unstructured":"Davaro F, Jain R, Li R. Immune checkpoint inhibitor toxicity management in Non-muscle-invasive bladder cancer: what urologists need to know. Eur Urol Focus; 2023;9(4):579.","DOI":"10.1016\/j.euf.2023.04.011"},{"issue":"4","key":"3667_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"issue":"3","key":"3667_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/bco2.220","volume":"4","author":"VK Woodcock","year":"2023","unstructured":"Woodcock VK, Chen JL, Purshouse K, Butcher C, Collins L, Haddon C, et al. PemBla: A phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer. BJUI Compass. 2023;4(3):322\u201330.","journal-title":"BJUI Compass"},{"issue":"1","key":"3667_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","volume":"56","author":"M Tichet","year":"2023","unstructured":"Tichet M, Wullschleger S, Chryplewicz A, Fournier N, Marcone R, Kauzlaric A, et al. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8(+) T cells and reprogramming macrophages. Immunity. 2023;56(1):162\u201379. e6.","journal-title":"Immunity"},{"issue":"7","key":"3667_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-024-02060-1","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Nogapendekin Alfa inbakicept: first approval. Drugs. 2024;84(7):867\u201374.","journal-title":"Drugs"},{"issue":"1","key":"3667_CR15","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, et al. IL-15 superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive bladder cancer. NEJM Evid. 2023;2(1):EVIDoa2200167.","journal-title":"NEJM Evid"},{"issue":"1","key":"3667_CR16","doi-asserted-by":"publisher","first-page":"1912885","DOI":"10.1080\/2162402X.2021.1912885","volume":"10","author":"CJ Rosser","year":"2021","unstructured":"Rosser CJ, Tikhonenkov S, Nix JW, Chan OTM, Ianculescu I, Reddy S, et al. Safety, Tolerability, and Long-Term clinical outcomes of an IL-15 analogue (N-803) admixed with Bacillus Calmette-Guerin (BCG) for the treatment of bladder cancer. Oncoimmunology. 2021;10(1):1912885.","journal-title":"Oncoimmunology"},{"key":"3667_CR17","doi-asserted-by":"publisher","first-page":"100400","DOI":"10.1016\/j.pacs.2022.100400","volume":"28","author":"E Alchera","year":"2022","unstructured":"Alchera E, Monieri M, Maturi M, Locatelli I, Locatelli E, Tortorella S, et al. Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods. Photoacoustics. 2022;28:100400.","journal-title":"Photoacoustics"},{"issue":"37","key":"3667_CR18","doi-asserted-by":"publisher","first-page":"e2411583121","DOI":"10.1073\/pnas.2411583121","volume":"121","author":"P Armanetti","year":"2024","unstructured":"Armanetti P, Locatelli I, Venegoni C, Alchera E, Campanella B, Pederzoli F, et al. Gold nanorod-assisted theranostic solution for nonvisible residual disease in bladder cancer. Proc Natl Acad Sci U S A. 2024;121(37):e2411583121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"3667_CR19","doi-asserted-by":"publisher","first-page":"e2403314","DOI":"10.1002\/adhm.202403314","volume":"14","author":"C Venegoni","year":"2025","unstructured":"Venegoni C, Tortorella S, Caliendo A, Locatelli I, Coste AD, Locatelli E, et al. Urine-Stable Aptamer-Conjugated gold nanorods for the early detection of High-Grade bladder cancer residual disease. Adv Healthc Mater. 2025;14(10):e2403314.","journal-title":"Adv Healthc Mater"},{"issue":"5","key":"3667_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1097\/JU.0000000000001576","volume":"205","author":"AN Kirschner","year":"2021","unstructured":"Kirschner AN, Wang J, Rajkumar-Calkins A, Neuzil KE, Chang SS. Intravesical Anti-PD-1 immune checkpoint Inhibition treats urothelial bladder cancer in a mouse model. J Urol. 2021;205(5):1336\u201343.","journal-title":"J Urol"},{"issue":"5","key":"3667_CR21","doi-asserted-by":"publisher","first-page":"e12671","DOI":"10.1016\/j.urology.2010.03.028","volume":"76","author":"M Horinaga","year":"2010","unstructured":"Horinaga M, Fukuyama R, Iida M, Yanaihara H, Nakahira Y, Nonaka S, et al. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology. 2010;76(5):e12671\u20136.","journal-title":"Urology"},{"issue":"4","key":"3667_CR22","first-page":"202","volume":"15","author":"R Kelsey","year":"2018","unstructured":"Kelsey R. Bladder cancer: BBN mouse model mimics human MIBC. Nat Rev Urol. 2018;15(4):202.","journal-title":"Nat Rev Urol"},{"issue":"7930","key":"3667_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells. Nature. 2022;610(7930):161\u201372.","journal-title":"Nature"},{"issue":"5","key":"3667_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2023.12.014","volume":"85","author":"F Pederzoli","year":"2024","unstructured":"Pederzoli F, Riba M, Venegoni C, Marandino L, Bandini M, Alchera E, et al. Stool Microbiome signature associated with response to neoadjuvant pembrolizumab in patients with Muscle-invasive bladder cancer. Eur Urol. 2024;85(5):417\u201321.","journal-title":"Eur Urol"},{"issue":"1","key":"3667_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12967-019-1778-6","volume":"17","author":"H Furuya","year":"2019","unstructured":"Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, et al. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. J Transl Med. 2019;17(1):29.","journal-title":"J Transl Med"},{"issue":"1","key":"3667_CR26","first-page":"4","volume":"15","author":"A MohanaSundaram","year":"2025","unstructured":"MohanaSundaram A, Raja V, Kamalakannan Y, Islam MA. Nogapendekin Alfa Inbakicept-pmln (Anktiva) with BCG: A promising arsenal in BCG-Unresponsive Non-Muscle-Invasive bladder cancer intervention. Adv Pharm Bull. 2025;15(1):4\u20136.","journal-title":"Adv Pharm Bull"},{"issue":"7\u20138","key":"3667_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41417-019-0155-1","volume":"27","author":"LF Chai","year":"2020","unstructured":"Chai LF, Prince E, Pillarisetty VG, Katz SC. Challenges in assessing solid tumor responses to immunotherapy. Cancer Gene Ther. 2020;27(7\u20138):528\u201338.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"3667_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","volume":"74","author":"MF Chevalier","year":"2018","unstructured":"Chevalier MF, Schneider AK, Cesson V, Dartiguenave F, Lucca I, Jichlinski P, et al. Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and May limit its efficacy. Eur Urol. 2018;74(5):540\u20134.","journal-title":"Eur Urol"},{"issue":"6","key":"3667_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3667_CR30","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig AM, Kaech SM, Wherry EJ. CD8(+) T cells in the cancer-immunity cycle. Immunity. 2023;56(10):2231\u201353.","journal-title":"Immunity"},{"issue":"9","key":"3667_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30(9):695\u2013704.","journal-title":"Trends Cell Biol"},{"issue":"5","key":"3667_CR32","doi-asserted-by":"publisher","first-page":"e1134412","DOI":"10.1080\/2162402X.2015.1134412","volume":"5","author":"AS Baras","year":"2016","unstructured":"Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5(5):e1134412.","journal-title":"Oncoimmunology"},{"issue":"7","key":"3667_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/bjs.10127","volume":"103","author":"Y Asano","year":"2016","unstructured":"Asano Y, Kashiwagi S, Goto W, Kurata K, Noda S, Takashima T, et al. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 2016;103(7):845\u201354.","journal-title":"Br J Surg"},{"issue":"1","key":"3667_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12672-022-00482-5","volume":"13","author":"N Goda","year":"2022","unstructured":"Goda N, Sasada S, Shigematsu H, Masumoto N, Arihiro K, Nishikawa H, et al. The ratio of CD8\u2009+\u2009lymphocytes to tumor-infiltrating suppressive FOXP3\u2009+\u2009effector regulatory T cells is associated with treatment response in invasive breast cancer. Discov Oncol. 2022;13(1):27.","journal-title":"Discov Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03667-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:03:58Z","timestamp":1781633038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03667-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3667"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03667-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Frozen single-cell suspensions of human PBMCs and TILs obtained from bladder cancer patients were purchased from Discovery Life Sciences (Huntsville, AL).All procedures and studies involving mice were approved by the Institutional Animal Care and Use Committee of San Raffaele Scientific Institute and performed according to the prescribed guidelines (IACUC approval #1430).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IL, ML, CV, ADC, RS, JJ, MB, DMC, AS, FM, MM, MA declare no competing financial interest. LCD, VN, CK, and PU are named inventors on a patent application (No. 15\/943,237) filed by Roche that is relevant to this work. PW, AM, VN are employees of Roche and declare ownership of Roche stock. CK, RJH, PU, and LCD are former employees of Roche, hold Roche stock, and are named inventors on Roche patents and\/or receive related royalties.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}